Ono Pharmaceutical Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gyo Sagara
- Full Time Employees
- 3,853
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 8-2, Kyutaromachi 1-chome Osaka Japan 541-8564
- IPO Date
- Mar 21, 2013
- Website
- ono-pharma.com
- Similar Companies
- Business
- Ono Pharmaceutical Co., Ltd. (ticker: OPHLF) manufactures, procures, and markets prescription pharmaceuticals and diagnostic reagents worldwide, with a focus on oncology, immunology, neurology, and related therapeutic areas of unmet medical needs; core products include Opdivo (nivolumab) intravenous infusion for various cancers marketed in collaboration with Bristol Myers Squibb, BRAFTOVI (encorafenib) capsules for BRAF-mutated cancers, Qinlock (ripretinib) for gastrointestinal stromal tumors, ROMVIMZA (vimseltinib) for tenosynovial giant cell tumor, tirabrutinib hydrochloride for primary central nervous system lymphoma, landiolol hydrochloride for tachycardia, small molecule drugs, monoclonal antibodies, synthetic peptides, and bispecific antibodies targeting mechanisms such as LAG3 inhibitors, CSF-1R antagonists, BTK, PDGFRα, c-Kit, β1-adrenergic receptor, and BRAF V600E. Founded in 1717 and headquartered in Chuo-ku, Osaka, Japan, the company operates primarily in Japan, the United States, Europe, Asia, and Taiwan through subsidiaries including ONO PHARMA USA Inc., ONO PHARMA UK Ltd., and Deciphera Pharmaceuticals Inc., with major production facilities in Higashinari-ku Osaka and Fujinomiya Shizuoka, and a central research institute in Minase, Osaka. Recent developments include the June 2024 acquisition of Deciphera Pharmaceuticals for $2.4 billion to bolster its oncology pipeline and global commercial presence in the US and Europe, a February 2025 reorganization integrating Deciphera as the key hub for R&D and sales/marketing in those regions while ceasing certain UK R&D operations, US FDA approvals in 2025 for vimseltinib and various Opdivo combinations in colorectal cancer, hepatocellular carcinoma, and other indications, European Commission approvals for ROMVIMZA and subcutaneous Opdivo formulations, a June 2025 strategic agreement with Vertex for povetacicept development in Japan and South Korea, license agreements with Ionis for sapablursen and Seikagaku for Gel-One osteoarthritis treatment, research collaborations with Jorna Therapeutics and Reborna Biosciences for novel RNA editing and CNS therapeutics, and supplemental approvals in Japan and Asia for Opdivo-Yervoy combinations and BRAFTOVI in colorectal cancer.
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P.
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call Transcript
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
ONO to buy Deciphera Pharmaceuticals at a huge premium
ONO to buy Deciphera Pharmaceuticals at a huge premium
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion
Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion
Ono Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's Why